Zaidoon A. Al-Zubaidy is a clinical development executive with over 20 years of experience in clinical end point trials in patient populations and bioequivalence in healthy volunteers.
Zaidoon was the VP Operations then the Executive Scientific Liaison for Akesis, responsible for building the privately owned quality driven contract research organization providing dermatology clinical research services, program management, and regulatory affairs services to pharmaceutical, device, generic, formulation development and biotech companies.
Prior to Akesis, Zaidoon was the Senior Director, Biopharmaceutics at Actavis Inc. responsible for developing and implementing a clinical and biopharmaceutics program to support an R&D team devoted to the R&D of new generic drug products. Prior to Actavis Inc., Zaidoon served as the Director of R&D and Clinical Development at Interpharm Inc., New York. He was responsible for advanced research towards the development of generic pharmaceutical products and for the biopharmaceutic assessment of pharmaceutical products to determine their readiness for bioequivalence studies.
Mr. Al-Zubaidy has managed the overall clinical program for Sandoz Canada, with global experience with clinical research organizations (CROs) from India, South Africa and North America.
Prior to working for generic pharmaceutical companies, Zaidoon spent 3 years as a pharmacokinetic manager at a global CRO, responsible for the interpretation of pharmacokinetic data & compilation of pharmacokinetic related reports.
Zaidoon A. Al-Zubaidy served as the Chair of the Bioequivalence Committee for the Canadian Generic Pharmaceutical Association, representing the Canadian generic industry’s concerns to Health Canada, to work with the government agency.
He is a graduate of the University of East London, UK (B.Sc. Pharmacology) and earned a Master’s degree from the University of Alberta, Canada (Physiology).
